Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.44 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.41 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.36 |
| ▸ | EDNRB | P24530 | 1/20 | 0.36 |
| ▸ | EDNRA | P25101 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4484659 | 0.86 | TRPA1 (0.52) | CYP2C9SCN9ATRPA1CYP1A2 | |
| SCHEMBL13754837 | 0.81 | TRPA1 (0.50) | CYP2C9SCN9ATRPA1CYP1A2MAPK14 | |
| SCHEMBL4564282 | 0.80 | SCN9A (0.50) | CYP2C9SCN9AABCC8KCNJ11ALOX5AP | |
| SCHEMBL4495572 | 0.77 | ALOX5AP (0.42) | CYP2C9SCN9AABCC8KCNJ11ALOX5AP | |
| SCHEMBL25011712 | 0.75 | CYP2C9 (0.50) | CYP2C9SCN9AALOX5APFEN1CYP3A4 | |
| SCHEMBL1041002 | 0.75 | HDAC3 (0.55) | HDAC3HDAC6NCOR2 | |
| SCHEMBL1400156 | 0.72 | SCN9A (0.60) | CYP2C9SCN9ATRPA1CYP3A4CYP2D6 | |
| SCHEMBL13754839 | 0.72 | BRD4 (0.53) | SCN9AALOX5APFEN1KDRSCN5A | |
| SCHEMBL24017179 | 0.72 | SCN9A (0.44) | CYP2C9SCN9AALOX5APFEN1EDNRB | |
| SCHEMBL25407073 | 0.72 | IKBKB (0.49) | CYP2C9IKBKBCYP1A2IDO1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572822-B2 | Biaryl substituted triazoles as sodium channel blockers | MERCK & CO. INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572822-B2 | Biaryl substituted triazoles as sodium channel blockers | MERCK & CO. INC. (US) | 2009-08-11 | — | — | US | disclosed |
| EP-1606269-B1 | BIARYL SUBSTITUTED TRIAZOLES AS SODIUM CHANNEL BLOCKERS | MERCK & CO INC (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1606269-B1 | BIARYL SUBSTITUTED TRIAZOLES AS SODIUM CHANNEL BLOCKERS | MERCK & CO INC (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20080171777-A1 | Biaryl substituted triazoles as sodium channel blockers | MERCK SHARP & DOHME LLC | 2008-07-17 | — | — | US | disclosed |
| US-20080171777-A1 | Biaryl substituted triazoles as sodium channel blockers | MERCK SHARP & DOHME LLC | 2008-07-17 | — | — | US | disclosed |
| US-7326726-B2 | Biaryl substituted triazoles as sodium channel blockers | MERCK & CO., INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-7326726-B2 | Biaryl substituted triazoles as sodium channel blockers | MERCK & CO., INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-20060183897-A1 | Biaryl substituted triazoles as sodium channel blockers | MERCK & CO., INC. | 2006-08-17 | — | — | US | disclosed |
| US-20050119261-A1 | Biaryl substituted triazoles as sodium channnel blockers | MERCK SHARP & DOHME LLC | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171777-A1 | Biaryl substituted triazoles as sodium channel blockers | SCN3A, TRPV1, SCN1B | CYP2C9 349/4885SCN9A 56/4885ABCC8 1220/4885 |
| US-20050119261-A1 | Biaryl substituted triazoles as sodium channnel blockers | SCN3A, TRPV1, KCNN3 | CYP2C9 279/4885SCN9A 67/4885ABCC8 665/4885 |
| US-20060183897-A1 | Biaryl substituted triazoles as sodium channel blockers | SCN3A, TRPV1, SCN1B | CYP2C9 349/4885SCN9A 56/4885ABCC8 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.